A Phase 3 interventional study of Etelcalcetide and Cinacalcet in Secondary Hyperparathyroidism and Chronic Kidney Disease, sponsored by Amgen. Completed at 90 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-30.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary — 2 open to participants now, 2 under way, 2 of them phase 3. etelcalcetide · Hyperparathyroidism, Secondary.
Among the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, this one is the 4th largest by enrollment, is one of 2 that started in 2018, is one of 9 in phase 3, and was the 14th registered.
188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.
Browse Hyperparathyroidism, Secondary studies →2 of the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary are open now, in 12 countries. Recruiting first, the newest first:
Amgen · Sites in Belgium, Czechia, France and 9 more countries
Ages 2–17
Amgen · Sites in United States, Argentina, India and 7 more countries
Ages 0–18
By country, each count listing its studies:
etelcalcetide: first FDA approval 2017 (PARSABIV), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2018.
This study's enrollment of 637 is above the median of 62 across 146 interventional studies indexed under Hyperparathyroidism, Secondary.
Median enrollment 72 across the 16 interventional studies. Of the 14 that completed or were terminated, 14 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 2 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
33 studies in Hyperparathyroidism, Secondary by Amgen: 2 open now, 2 under way, 2 of them phase 3. Of 31 finished, 22 (71%) have results posted.
Among the 33 studies in Hyperparathyroidism, Secondary by Amgen, this one is the 6th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2018, is one of 16 in phase 3, and was the 31st registered.
Amgen’s Hyperparathyroidism, Secondary studies by the year they started, since 2001.
1 of the studies testing etelcalcetide in Hyperparathyroidism, Secondary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 33 in Hyperparathyroidism, Secondary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum intact parathyroid hormone (PTH) levels by > 30% from baseline among participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) who require management with hemodialysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subject has abnormalities on prestudy clinical examination or abnormalities on the most recent central laboratory tests during the screening period prior to randomization according to the Investigator including but not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were randomized to receive oral cinacalcet once daily and placebo intravenous (IV) bolus injection at the end of each hemodialysis session three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 25 mg daily and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum parathyroid hormone (PTH) ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
Drug: Cinacalcet
Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
Drug: Etelcalcetide
Administered intravenously three times per week.
Also known as: AMG 416, Parsabiv®
Cinacalcet administered orally once a day.
Also known as: Sensipar®, Mimpara®
Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis
Predialysis intact parathyroid hormone (iPTH) levels were measured by a central laboratory.
Time frame: Baseline and the efficacy assessment phase (EAP; defined as weeks 20 to 27, inclusive).
Percentage of Participants With > 50% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase
Predialysis intact parathyroid hormone levels were measured by a central laboratory.
Time frame: Baseline and the efficacy assessment phase (weeks 20 to 27, inclusive).
Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase - Superiority Analysis
Predialysis intact parathyroid hormone levels were measured by a central laboratory.
Time frame: Baseline and the efficacy assessment phase (weeks 20 to 27, inclusive)
Percent Change From Baseline in Mean Predialysis Corrected Calcium During the Efficacy Assessment Phase
Predialysis corrected calcium was measured by a central laboratory.
Time frame: Baseline and the efficacy assessment phase (weeks 20 - 27, inclusive)
Percentage of Participants With Mean Predialysis Serum Phosphorus ≤ 4.5 mg/dL During the Efficacy Assessment Phase
Predialysis serum phosphorus was measured by a central laboratory.
Time frame: Efficacy assessment phase (weeks 20 - 27, inclusive)
Number of Participants With cCa < 8.3 mg/dL At Any Time During the Study
Corrected calcium was measured by the central laboratory.
Time frame: From first dose of study drug to end of study; up to 26 weeks + 30 days.
Number of Participants With cCa < 8.0 mg/dL At Any Time During the Study
Corrected calcium was measured by the central laboratory.
Time frame: From first dose of study drug to end of study; up to 26 weeks + 30 days.
Number of Participants With cCa < 7.5 mg/dL At Any Time During the Study
Corrected calcium was measured by the central laboratory.
Time frame: From first dose of study drug to end of study; up to 26 weeks + 30 days.
Number of Participants With Treatment-emergent Symptomatic Hypocalcemia During the Study
Common symptoms of hypocalcemia (diminished blood calcium) include paresthesias (fingertips, toes, or perioral), fatigue, muscle cramps, irritability or anxiety, tetany (eg, carpopedal spasm, laryngospasm), Chvostek's sign, seizures, and prolonged QT interval.
Time frame: From first dose of study drug to 30 days after last dose; up to 26 weeks + 30 days.
Number of Participants Who Developed Antibodies to Etelcalcetide
Developing antibody incidence is defined as participants who were binding antibody positive post-baseline with a negative or no result at baseline.
Time frame: From first dose of study drug to 30 days after last dose; up to 26 weeks + 30 days.
Number of Participants With Treatment-emergent Adverse Events
An adverse event is defined as any untoward medical occurrence in a clinical study participant, including worsening of a pre-existing medical condition. The event does not necessarily have a causal relationship with study treatment. The investigator assessed whether each adverse event was possibly related to study drug. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event
Time frame: From first dose of study drug to 30 days after last dose; up to 26 weeks + 30 days.
This study was conducted at 84 centers including mainland China (43 centers), Hong Kong (2 centers), India (12 centers), South Korea (11 centers), Malaysia (4 centers), and Taiwan (12 centers). Participants were enrolled from 15 May 2018 to 12 September 2019.
| Milestone | Cinacalcet | Etelcalcetide |
|---|---|---|
| Started | 317 | 320 |
| Received treatment | 315 | 318 |
| Completed | 270 | 282 |
| Not completed | 47 | 38 |
| Withdrew: Withdrawal by subject | 34 | 29 |
| Withdrew: Decision by sponsor | 4 | 5 |
| Withdrew: Death | 9 | 4 |
Predialysis intact parathyroid hormone (iPTH) levels were measured by a central laboratory.
| percentage of participants | Cinacalcet | Etelcalcetide |
|---|---|---|
| Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis | 66.2 | 71.9 |
Predialysis intact parathyroid hormone levels were measured by a central laboratory.
| percentage of participants | Cinacalcet | Etelcalcetide |
|---|---|---|
| Percentage of Participants With > 50% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase | 41.6 | 59.1 |
Predialysis intact parathyroid hormone levels were measured by a central laboratory.
| percentage of participants | Cinacalcet | Etelcalcetide |
|---|---|---|
| Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase - Superiority Analysis | 58.0 | 66.3 |
Predialysis corrected calcium was measured by a central laboratory.
| percent change | Cinacalcet | Etelcalcetide |
|---|---|---|
| Percent Change From Baseline in Mean Predialysis Corrected Calcium During the Efficacy Assessment Phase | -8.00 ± 0.50 | -10.69 ± 0.53 |
Predialysis serum phosphorus was measured by a central laboratory.
| percentage of participants | Cinacalcet | Etelcalcetide |
|---|---|---|
| Percentage of Participants With Mean Predialysis Serum Phosphorus ≤ 4.5 mg/dL During the Efficacy Assessment Phase | 26.2 | 29.1 |
Corrected calcium was measured by the central laboratory.
| Participants | Cinacalcet | Etelcalcetide |
|---|---|---|
| Number of Participants With cCa < 8.3 mg/dL At Any Time During the Study | 245 | 273 |
Corrected calcium was measured by the central laboratory.
| Participants | Cinacalcet | Etelcalcetide |
|---|---|---|
| Number of Participants With cCa < 8.0 mg/dL At Any Time During the Study | 194 | 241 |
Corrected calcium was measured by the central laboratory.
| Participants | Cinacalcet | Etelcalcetide |
|---|---|---|
| Number of Participants With cCa < 7.5 mg/dL At Any Time During the Study | 61 | 109 |
Common symptoms of hypocalcemia (diminished blood calcium) include paresthesias (fingertips, toes, or perioral), fatigue, muscle cramps, irritability or anxiety, tetany (eg, carpopedal spasm, laryngospasm), Chvostek's sign, seizures, and prolonged QT interval.
| Participants | Cinacalcet | Etelcalcetide |
|---|---|---|
| Number of Participants With Treatment-emergent Symptomatic Hypocalcemia During the Study | 15 | 35 |
Developing antibody incidence is defined as participants who were binding antibody positive post-baseline with a negative or no result at baseline.
| Participants | Etelcalcetide |
|---|---|
| Number of Participants Who Developed Antibodies to Etelcalcetide | 18 |
An adverse event is defined as any untoward medical occurrence in a clinical study participant, including worsening of a pre-existing medical condition. The event does not necessarily have a causal relationship with study treatment. The investigator assessed whether each adverse event was possibly related to study drug. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event
| Participants | Cinacalcet | Etelcalcetide |
|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 303 | 306 |
| Serious adverse events | 61 | 53 |
| TEAEs leading to discontinuation of study drug | 15 | 9 |
| Fatal adverse events | 9 | 4 |
| Treatment-related TEAEs | 243 | 250 |
| Treatment-related serious adverse events | 4 | 4 |
| Treatment-related TEAEs leading to discontinuation of study drug | 5 | 3 |
| Treatment-related fatal adverse events | 1 | 1 |
Collected over From first dose of study drug to 30 days after last dose (up to 26 weeks + 30 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cinacalcet | 9/317 (2.8%) | 61/315 (19.4%) | 293/315 (93%) |
| Etelcalcetide | 4/320 (1.3%) | 53/318 (16.7%) | 294/318 (92.5%) |
| Event | Cinacalcet | Etelcalcetide |
|---|---|---|
| PneumoniaInfections and infestations | 4/315 | 7/318 |
| Arteriovenous fistula occlusionInjury, poisoning and procedural complications | 3/315 | 5/318 |
| HypertensionVascular disorders | 1/315 | 4/318 |
| Acute myocardial infarctionCardiac disorders | 3/315 | 0/318 |
| End stage renal diseaseRenal and urinary disorders | 2/315 | 3/318 |
| Arteriosclerosis coronary arteryCardiac disorders | 2/315 | 0/318 |
| Cardiac failure acuteCardiac disorders | 2/315 | 2/318 |
| Coronary artery diseaseCardiac disorders | 2/315 | 0/318 |
| CataractEye disorders | 2/315 | 0/318 |
| PeritonitisInfections and infestations | 2/315 | 1/318 |
| Event | Cinacalcet | Etelcalcetide |
|---|---|---|
| Blood calcium decreasedInvestigations | 218/315 | 252/318 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 37/315 | 48/318 |
| VomitingGastrointestinal disorders | 47/315 | 30/318 |
| NauseaGastrointestinal disorders | 45/315 | 35/318 |
| HypocalcaemiaMetabolism and nutrition disorders | 15/315 | 35/318 |
| HyperphosphataemiaMetabolism and nutrition disorders | 34/315 | 26/318 |
| Upper respiratory tract infectionInfections and infestations | 33/315 | 34/318 |
| HypotensionVascular disorders | 27/315 | 34/318 |
| NasopharyngitisInfections and infestations | 31/315 | 28/318 |
| CoughRespiratory, thoracic and mediastinal disorders | 29/315 | 23/318 |
The full analysis set includes all randomized participants.
| Age, Continuous(years) | Cinacalcet | Etelcalcetide | Total |
|---|---|---|---|
| Mean | 51.5 ± 12.9 | 52.2 ± 13.4 | 51.8 ± 13.1 |
| Age, Customized(Participants) | Cinacalcet | Etelcalcetide | Total |
|---|---|---|---|
| 18 - 64 years | 264 | 262 | 526 |
| 65 - 74 years | 45 | 47 | 92 |
| 75 - 84 years | 8 | 9 | 17 |
| ≥ 85 years | 0 | 2 | 2 |
| Sex: Female, Male(Participants) | Cinacalcet | Etelcalcetide | Total |
|---|---|---|---|
| Female | 138 | 142 | 280 |
| Male | 179 | 178 | 357 |
| Race/Ethnicity, Customized(Participants) | Cinacalcet | Etelcalcetide | Total |
|---|---|---|---|
| Asian Indian | 19 | 19 | 38 |
| Chinese | 262 | 270 | 532 |
| Other | 36 | 31 | 67 |
| Stratification Factor: Screening Intact Parathyroid Hormone (iPTH)(Participants) | Cinacalcet | Etelcalcetide | Total |
|---|---|---|---|
| < 900 pg/mL | 128 | 131 | 259 |
| ≥ 900 pg/mL | 189 | 189 | 378 |
| Stratification Factor: Screening Corrected Calcium (cCa)(Participants) | Cinacalcet | Etelcalcetide | Total |
|---|---|---|---|
| < 9 mg/dL | 62 | 64 | 126 |
| ≥ 9 mg/dL | 255 | 256 | 511 |
| Stratification Factor: Country/Region(Participants) | Cinacalcet | Etelcalcetide | Total |
|---|---|---|---|
| China | 189 | 191 | 380 |
| Non-China | 128 | 129 | 257 |
| Intact Parathyroid Hormone Level(pg/mL) | Cinacalcet | Etelcalcetide | Total |
|---|---|---|---|
| Mean | 1299.01 ± 830.99 | 1299.91 ± 853.82 | 1299.46 ± 841.87 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from May 2018 to primary completion in Apr 2020, 22 months.
Results were first posted in Apr 2021, 1 year after primary completion.
Of 21 phase 3 interventional studies under Hyperparathyroidism, Secondary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 22 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etelcalcetide
Hyperparathyroidism, Secondary →